DELVE
Live / Applied — Suspended — suspension check completed, case still suspended (as of 24 Aug 2025)
What this means for you
Not registered yet, but its 03 Nov 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98254371
- Mark type
- Stylized text
- Filed
- 03 Nov 2023
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceuticals for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases
- Class 042 — Scientific and technological services: Medical research and development; research and development in the field of computational biology, bioinformatics, genetics, genomics, biotechnology, pharmaceuticals, and therapeutics; platform as a service (PaaS) featuring computer software platforms for drug discovery; pharmaceutical and biopharmaceutical research and development; drug development services, namely, pharmaceutical drug development services; development of pharmaceuticals and therapeutic agents for others, namely, development of pharmaceutical preparations and medicines; platform as a service (PaaS) featuring computer software platforms for enabling research and development of pharmaceutical data in the field of computational biology, bioinformatics, genetics, genomics, biotechnology and pharmaceuticals; DNA, RNA, and genomic analysis and sequencing services for medical research purposes; none of the foregoing relating to finding people scientific studies to participate in or recruiting participants for scientific studies
Owner
- PROLOGUE MEDICINES, INC., CAMBRIDGE, MA, US
- Flagship Labs 89, Inc., Cambridge, MA, US
Prosecution history
- 24 Aug 2025 — REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
- 10 Aug 2025 — REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
- 06 Feb 2025 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
- 27 Jun 2024 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 27 Jun 2024 — LETTER OF SUSPENSION E-MAILED
- 27 Jun 2024 — SUSPENSION LETTER WRITTEN
- 04 Jun 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 03 Jun 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 03 Jun 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 04 Mar 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 04 Mar 2024 — NON-FINAL ACTION E-MAILED
- 04 Mar 2024 — NON-FINAL ACTION WRITTEN
- 26 Jan 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 26 Jan 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 26 Jan 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED